Ascendis Pharma A/S (NASDAQ:ASND) PT Raised to $191.00 at Bank of America

Ascendis Pharma A/S (NASDAQ:ASND) had its target price boosted by equities researchers at Bank of America from $175.00 to $191.00 in a research note issued on Monday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s price objective would suggest a potential upside of 31.82% from the stock’s current price.

Several other research firms have also issued reports on ASND. TD Cowen lowered their price objective on Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Citigroup raised their price target on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Wells Fargo & Company boosted their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Oppenheimer restated an “outperform” rating and issued a $190.00 target price (up previously from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday, September 17th. Finally, StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Thursday, September 5th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $195.00.

Ascendis Pharma A/S Trading Down 1.2 %

Shares of NASDAQ:ASND opened at $144.89 on Monday. The company has a market cap of $8.44 billion, a price-to-earnings ratio of -15.08 and a beta of 0.63. Ascendis Pharma A/S has a 12 month low of $85.29 and a 12 month high of $161.00. The company has a 50-day moving average price of $133.83 and a 200 day moving average price of $136.49.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several hedge funds have recently made changes to their positions in ASND. Private Ocean LLC purchased a new position in shares of Ascendis Pharma A/S during the first quarter valued at $36,000. Quadrant Capital Group LLC grew its holdings in Ascendis Pharma A/S by 90.4% during the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares during the period. GAMMA Investing LLC raised its holdings in shares of Ascendis Pharma A/S by 52.0% in the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 102 shares in the last quarter. Finally, Barometer Capital Management Inc. purchased a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth approximately $126,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.